LIU Libin , ZHOU Hongyu.
  • Department of Neurology, West China Hospital, Sichuan University, Chengdu Sichuan, 610041, P.R.China.;
Myoblast; Gene therapy; Neurological disease; Angiocardiopathy; Hematopathy
Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables References Cited by

Objective To introduce the current situation and futureof myoblast transfer therapy (MTT) in clinical application Methods The latest fifteenyear literatures were extensively reviewed, concerninggene therapy for Duchenne’s muscular dystrophy, Parkinson’s disease, myelopathy, permanent facial paralysis, angiocardiopathy, injuries of bone, joint and muscle, hematopathy, and pituitary dwarf. Results In medical field, MTT is an ideal method to treat some common diseases. The problems were immunologic rejection and better carriers for myoblasts implantation. Conclusion It is the focus on the use of myoblast as a vector to carry exogenous gene in some disease therapy. The major problems of MTT include transplantation immunity, cell fusion and target protein expression. It is easy to gain,culture and transfuse to the host for myoblasts, these merits are beneficial to clinical application. 

Citation： LIU Libin,ZHOU Hongyu.. PRESENT AND FUTURE OF CLINICAL APPLICATION OF MYOBLAST. Chinese Journal of Reparative and Reconstructive Surgery, 2007, 21(7): 767-770. doi: Copy